Clinical Trial Update: A 16-Week Study to Evaluate the Efficacy, Safety, and Tolerability of GLY-200 in Participants With Obesity [Phase 2]

View source ↗

Summary

Phase 2 study completed evaluating GLY-200 in adults with obesity, reporting on efficacy, safety, and tolerability over 16 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• GLY-200

Snippet

Sponsor: Glyscend, Inc. | Conditions: Obesity | Phase 2 | Status: COMPLETED